A novel proteoliposomal vaccine elicits potent antitumor immunity in mice

Blood

Volumn 109, Issue 12, 2007, Pages 5407-5410

  Popescu, Mircea C ^a,e   Robb, Richard J ^a   Batenjany, Michael M ^b   Boni, Lawrence T ^b   Neville, Mary E ^b   Pennington, Robin W ^c   Neelapu, Sattva S ^d   Kwak, Larry W ^d  

^a XEME Biopharma   (United States)

^b Biomira USA Inc   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e XEME Biopharma Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANE PROTEIN; CYTOKINE; IMMUNOGLOBULIN; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; RECOMBINANT DNA; TUMOR VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; DRUG POTENCY; FEMALE; HYBRIDOMA; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOLIPOSOME; TUMOR IMMUNITY;

EID: 34250022642     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-039446     Document Type: Article

References (17)

1. Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327:1209-1215.
2. Hsu FJ, Caspar CB, Czerwinski DK, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood. 1997;89:3129-3135.
3. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5:1171-1177.
4. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99:1517-1526.
5. Boni LT, Batenjany MM, Neville ME, et al. Interleukin-2-induced small unilamellar vesicle coalescence. Biochem Biophys Acta. 2001;1514:127-138.
6. Kwak LW, Pennington R, Boni L, Ochoa AC, Robb RJ, Popescu MC. Cutting edge: liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J Immunol. 1998;160:3637-3641.
7. Neelapu SS, Baskar S, Gause BL, et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res. 2004;10:8309-8317.
8. Redfern CH, Guthrie TH, Bessudo A, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol. 2006;24:3107-3112.
9. Hurvitz SA, Timmerman JM. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol. Ther. 2005;5:841-852.
10. Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eb origin. Eur J Immunol. 1977;7:413-417.
11. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA. 1996;93:10972-10977.
12. Karrer U, Althage A, Odermatt B, et al. On the key role of secondary lymphoid organs in antiviral immune responses studied in a lymphoplastic (aly/aly) and spleenless (Hox11(-/-)) mutant mice. J Exp Med. 1997;185:2157-2170.
13. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998; 392:245-252.
14. Ludewig B, Barchiesi F, Pericin M, et al. In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective anti-viral and anti-tumor immunity. Vaccine. 2001;19:23-32.
15. Norbury CC, Basta S, Donohue KB, et al. CD8+ T cell cross-priming via transfer of proteasome substrates. Science. 2004;304:1318-1321.
16. Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TNM. Antigen bias in T cell cross-priming. Science. 2004;304:1314-1317.
17. Neelapu SS, Gause BL, Harvey L, et al. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood. 2007; 109:xxx-xxx.